Clinical Trials Logo

Corneal Neovascularization clinical trials

View clinical trials related to Corneal Neovascularization.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02797704 Terminated - Clinical trials for Corneal Neovascularization

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Start date: March 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this current study is to prospectively evaluate the influence of a single subconjunctival aflibercept injection on the regression of corneal neovascularization. Twenty patients with corneal neovascularization who are candidates for anti VEGF treatment (by the discretion of a corneal specialist) will be included in this study. The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization. Regression of neovascularization will be documented.

NCT ID: NCT01868360 Terminated - Clinical trials for Corneal Neovascularization

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Start date: June 2013
Phase: Phase 1
Study type: Interventional

The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. The current standard of care to prevent graft rejection includes use of topical steroids and medicines that suppress the immune system. These medicines do not address corneal neovascularization. The purpose of the study is to establish the safety and potential efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron) injection in inducing regression of blood vessels growing into the cornea and promoting graft survival. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.

NCT ID: NCT00915590 Terminated - Clinical trials for Corneal Neovascularization

Topical IL-1-Ra for Treatment of Corneal Neovascularization

Start date: April 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.